



THE SCRIPT

QUARTERLY NEWSLETTER
MISSISSIPPI BOARD OF PHARMACY

NEXT BOARD MEETINGS


Our next regularly scheduled board meetings will be held on:

- November 19, 2026
- January 21, 2027
- March 18, 2027
- May 20, 2027

at the Board of Pharmacy's office located at 6311 Ridgewood Road, Suite E 401 Jackson, MS. The meeting will begin at 9:00 a.m.

INSIDE THIS ISSUE

1. IMPORTANT RENEWAL INFO
2. TELEHEALTH
3. CE AUDITS
4. DIVERSION REPORTING



The more you prepare for me, the easier I become.

I arrive every year.

Some people finish me early, while others rush at the last minute.

I help keep licenses, permits, and registrations current.

Answer on Page 3

Joint Statement on Research-Grade and Non-FDA-Approved Peptides: Questions & Answers

Q: What does the statement non-FDA-approved peptide mean?

A: The joint statement focuses on research-grade peptides or peptides that do not have a valid pathway to compounding under the applicable 503a/503b guidelines. We recognize that no compounds are FDA-approved. The intent of this statement is not to forbid compounding that meets the criteria for allowed exemptions under federal and state laws.

Q: If I compound a peptide using active pharmaceutical ingredients supported by a certificate of analysis, does this statement apply?

A: A certificate of analysis alone does not satisfy the concerns of the statement. The bulk substance API would need to be appropriately sourced from an FDA-registered establishment and the peptide would need to satisfy all exemptions for compounding. Notably, the bulk substance would need to have an applicable USP or NF monograph, or be a component of an FDA-approved drug, or be on the applicable FDA bulk list, or be actively listed on the FDA Interim Category 1 Policy. Additionally, the bulk substance would need to satisfy conditions of not being essentially a copy of a commercially available drug product.

Q: Would providing a statement that the non-FDA-approved peptide is not to be used in humans alleviate advising or recommendation concerns?

A: No, a disclaimer against human use would not remove the potential for enforcement action.

Q: Would providing instructions either directly or through an unaffiliated website on how to dose a non-FDA-approved peptide be considered a forbidden action?

A: Recommending a non-FDA-approved peptide, such as by directly or indirectly providing dosage or use instructions or information, is prohibited and could result in enforcement action.

TELEHEALTH PRESCRIBERS: VERIFY MS LICENSURE

Be sure to verify that out-of-state doctors and nurse practitioners have a MS license if they are providing telehealth services for Mississippi patients. You can verify via the following links for doctors and nurse practitioners respectively:

<https://gateway.msblml.ms.gov/verification/search.aspx> or [License Verification | Mississippi Board of Nursing \(ms.gov\)](#)

Take Five for Your Well-Being

As the holiday season approaches, schedules become busier, patient needs increase, and many pharmacy professionals are working to finish continuing education, complete academic requirements, or prepare for year-end responsibilities.

In the midst of caring for others, take a few minutes to care for yourself.

The [APhA Well-Being](#) Index is a confidential self-assessment that helps pharmacists, pharmacy technicians, and student pharmacists evaluate their well-being and access helpful resources. It only takes a few minutes to complete but can provide valuable insight during one of the busiest times of the year.

As you wrap up the year and prepare for the season ahead, make your well-being part of your checklist. Your health matters, too.



Burnout is real.

Take advantage of APhA's online screening tool, invented by the Mayo Clinic, to evaluate your fatigue, depression, burnout, anxiety, and stress and assess your well-being.

It takes less than 5 minutes to answer 9 short questions.

It's 100% anonymous, free, and you do not need to be an APhA member.

Resources are available once you submit your assessment.

Well-being Index for Pharmacists, Student Pharmacists, & Pharmacy Technicians

www.pharmacist.com/wbi

Invitation Code: APhA

Or Scan



You're committed to pharmacy.
We're committed to your well-being.
www.pharmacist.com/wellbeing

ALL THINGS LICENSING



IMPORTANT RENEWAL REMINDERS

We are currently in the year-end renewal period, which will close at midnight on December 31, 2026. Any renewals submitted after this deadline will be subject to a late fee. If you do not wish to renew and/or need to close a facility permit, please log into the Gateway and submit a permit closure request.

Any renewal applications remaining in pending status after 12/31/2026 will result in an expired license. Individuals may not practice on an expired or pending license, and facilities may not operate under an expired or pending permit.

NEW TO LICENSING?

Essential information for pharmacists, technicians, students, permit holders, and facilities is available in the Licensee Resource Center:

- Gateway account management
- Name, employment, and address changes
- Renewals and amendments
- Verification requests
- NABP requirements
- Facility compliance reminders

Visit: <https://www.mbp.ms.gov/licensing>

WITHDRAWAL FROM PHARMACY SCHOOL

Please notify the Board immediately if you withdraw from pharmacy school. Student Intern/Extern registrations become inactive upon withdrawal. Should you wish to apply for a pharmacy technician registration, you will be required to petition the Board for permission.

LICENSE VERIFICATION

The license verification website is the primary source of credential verification information of all licensees, permittees, and registrants. Verification can be obtained through the License Verification site at <https://gateway.mbp.ms.gov/Verification/search.aspx>. Licensees, permittees, and registrants requiring official verification directly from the board may submit a Verification Request through their Licensure Gateway portal for a fee of \$25.00.



CONTACT INFORMATION REQUIREMENT

Each facility record must list at least two email addresses, one for the PIC/DR and one for an administrative contact. This ensures that all renewal notices, change application notifications, and other correspondence are received by the facility, even if the PIC/DR position becomes vacant.

DEVICES MATTER

When accessing the online system from a cell phone or tablet (any device other than a desktop or laptop), please be sure to use the drop-down/scroll feature. On certain devices, not all application options or system functions may be immediately visible.

We have had instances where individuals submitted the incorrect application because the scroll feature was not fully utilized on their device. To avoid this, please review the full menu carefully before proceeding.

If you encounter any issues, please don't hesitate to contact our Licensing Division. We are happy to assist you.

MEDICAL DEVICE ESTABLISHMENT

The new distinct license category of "Medical Device Establishment" was created for entities that solely manufacture or distribute medical devices. If a facility is involved in both devices and drugs, they should not pursue the "Medical Device Establishment" pathway.

Please note:

1. [73-21-105\(1\)](#), includes entities that are involved with prescription drugs and/or devices as entities that must register.
2. Please see the updated statutory definition of "[device](#)". This updated definition was an impetus for the creation of a "Medical Device Establishment" permit.
3. [Article XXXII](#), applies to the need for registration of devices in addition to drugs and APIs. While multiple facility types are listed in the article, this is not an exhaustive list, as stated within the article itself. The email were sent to Facilities stating that an entity that solely manufactures or distributes medical devices must register as a "Medical Device Establishment".

 **NABP PROFILE REMINDER**
CREATE A FREE PROFILE AT WWW.NABP.PHARMACY
REPORT YOUR E-PROFILE ID TO
LICENSING@MBP.MS.GOV

 **QUICK LINKS / CONTACT**
LICENSING WEBSITE:
[HTTPS://WWW.MBP.MS.GOV/LICENSING](https://WWW.MBP.MS.GOV/LICENSING)
LICENSING DIVISION: (601) 899-8880



PMP CLEARINGHOUSE

If your facility's reporting of controlled substances is being sent to the PMP clearinghouse automatically by your pharmacy software vendor, please ensure you have access to the email address used for the submitter account. A report of the day's submissions will be sent to that email address daily. This notifies the pharmacy if they have rejections, errors, or warnings that need to be addressed. All errors or rejections in the MSPMP database are **required** to be corrected. It is pertinent to have access to the daily PMP submission reports to identify errors or if your submissions were not sent successfully. Please refer to the [Data Submission Guide](#) should you need assistance making these corrections.

REPORTING TO THE PMP

Controlled substance prescriptions sent to the MSPMP database without a valid DEA number will receive a rejection. Drugs of concern are required to be reported. The current drug of concern in Mississippi is gabapentin. When reporting gabapentin, **DO NOT USE A FALSE DEA NUMBER**. Please use the provider's valid DEA number. For gabapentin prescriptions from a provider that does not hold a DEA registration, use their NPI number. Should the prescription be from a veterinarian that does not have a DEA registration, please use that veterinarian's state issued license number.



CONTINUING EDUCATION OPPORTUNITY

Earn 1 Hour of Free ACPE Credit!

Developed with the National Association of State Controlled Substance Authorities and 12 prescription monitoring programs.

Learn how data entry impacts PMP data, clinical decisions, and downstream analysis.

Available until October 20, 2026.

VIEW CE: [TALEM HEALTH CE PROGRAM](#)

REMINDER



DIVERSION REPORTING

- Any suspicion of diversion should be reported promptly.
- Unsure where to report? Contact MS PMP directly for guidance.



PMP REPORT REQUESTS

- Individuals must contact MS PMP directly for their PMP reports.
- **Do not share PMP reports with anyone.**



PERMIT & DEA UPDATES

Notify MS PMP if:

- Your permit becomes inactive or closed
- Your pharmacy has a change of DEA number
- This ensures your pharmacy's reporting remains accurate and compliant.

QUESTIONS? CONTACT MS PMP:

✉ MSPMPASSIST@MBP.MS.GOV | ☎ 601-899-0138

🌐 WWW.PMP.MBP.MS.GOV

COMPLIANCE CHECK



COMPOUNDING STATISTICAL REPORT

Don't forget to submit your Compounding Statistical Report no later than January 31, 2027! This report must be filed with the Mississippi Board of Pharmacy each year for every pharmacy that has a compounding certificate. Compounding data submitted will cover January 1, 2026, through December 31, 2026 so you will not submit the form until after December 31, 2026. The form can be found in the Gateway Portal- see below for instructions beginning in January 2027.

Pathway to Upload Your Compounding Statistical Report (DUE January 31, 2027)

- Only for Sterile Compounds. If you only compound non-sterile, report zero.
- Only applicable if you have a compounding certificate.
- You are not required to submit a recent compounding inspection since this was already submitted with your renewal application.

👉 For full instructions on how to submit, visit [Compounding Statistical Report Information](#).

CE AUDITS

We gather documentation for our CE audits electronically. CE Audits are triggered by license renewals. When you launch your pharmacist renewal application, you will receive notification if you have been chosen for the CE Audit. If chosen for the audit, you will need to provide documentation of CE obtained from January 1, 2025, through December 31, 2025 by uploading it to the gateway within 5 days. You are responsible for providing the documentation within the requested time frame. Please be sure to follow through to avoid any disciplinary action related to not providing the required CE documentation or not providing the documentation within the required time frame. If you have any questions regarding CE audits, please reach out to us at 601-899-8880 or email us at compliance@mbp.ms.gov.

Continuing Education Requirements (Summary)

- 15 hours of CE required for each licensure period
- 2 hours live CE (live seminar or live webinar-no recordings) NOTE: Live CE is attained in the presence of other pharmacists with a presenter and the possibility of interaction with a peer group. Webinars are considered live CE if the pharmacist can ask questions and get answers from the presenter(s) or the moderator during the webinar.
- 2 hours opioid abuse and prevention or other addiction related issue
- ACPE or MS BOP approved
- See Article IV of the MS Pharmacy Practice Regulations

